ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
TRT and erythrocytosis
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 271143" data-attributes="member: 13851"><p><em><strong>*Of the various formulations, intramuscular injections have an estimated rate of erythrocytosis of 40% followed by subcutaneous pellets at 35%. Short-acting TT through transdermal and Androgel has been associated with lower rates of polycythemia; 15% and 3% respectively. <u>The safest formulations include intranasal testosterone (0–2%) and oral testosterone (0.03%)</u> [11, 35, 36]</strong></em></p><p><em><strong></strong></em></p><p><em><strong><em><strong>*The Endocrine Society uses a hematocrit threshold of <u>>50%</u> as a relative contraindication to initiating TT and <u>>54%</u> as an indication to discontinue treatment [1]. The European Association of Urology (EAU) guidelines on hypogonadism also state that the hematocrit should not exceed <u>54%</u>, while recent Canadian guidelines cite <u>55%</u> as the safe upper limit [15, 40]. The AUA guidelines on testosterone deficiency define polycythemia as a hematocrit of <u>52%</u> and recommend stopping or reducing treatment if the hematocrit reaches 54% [14]</strong></em></strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 271143, member: 13851"] [I][B]*Of the various formulations, intramuscular injections have an estimated rate of erythrocytosis of 40% followed by subcutaneous pellets at 35%. Short-acting TT through transdermal and Androgel has been associated with lower rates of polycythemia; 15% and 3% respectively. [U]The safest formulations include intranasal testosterone (0–2%) and oral testosterone (0.03%)[/U] [11, 35, 36] [I][B]*The Endocrine Society uses a hematocrit threshold of [U]>50%[/U] as a relative contraindication to initiating TT and [U]>54%[/U] as an indication to discontinue treatment [1]. The European Association of Urology (EAU) guidelines on hypogonadism also state that the hematocrit should not exceed [U]54%[/U], while recent Canadian guidelines cite [U]55%[/U] as the safe upper limit [15, 40]. The AUA guidelines on testosterone deficiency define polycythemia as a hematocrit of [U]52%[/U] and recommend stopping or reducing treatment if the hematocrit reaches 54% [14][/B][/I][/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
TRT and erythrocytosis
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top